doi: 10.1007/s40572-022-00360-w
A1c 8.7 24/04/2025 A1c 6.6 @Cylan said: Meginersaid: @meginer said: The laboratory told me that although it was not on a technical file, it could be used in type 1 and it was still studying but what little there was, it was in favor.It is really a tto or obesity and not for DB 1, it can have an effect on glycemia but little since our problem is that we have no insulin, with what I do not think it is a serious problem It really is a treatment for type 2 diabetes that has results from rebound that helps with obesity.So lower blood sugar so it should be taken into account for the administration of insulin in type 1
Conclusions/interpretation At current prices, use of SGLT2is, but not GLP-1 RAs, would be cost-effective when considering only their cardiovascular and kidney disease benefits for people with type 2 diabetes
Top-line outcomes at the 48-week primary endpoint, by dose: Secondary endpoint magnitudes at the 12mg cohort: approximately 41% mean reduction in fasting insulin
Until oral GLP-1 formulations become widely available and proven for weight loss, Qsymia remains the strongest oral option
Treatments in ischemic stroke: current and future
